Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2020

Study Completion Date

October 31, 2020

Conditions
HIV Infection
Interventions
DRUG

DTG +DRV/r

NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)

DRUG

SOC

Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)

Trial Locations (31)

Unknown

Hospital Garrahan, Buenos Aires

Centre Hospitalier Andrée Rosemon, Cannes

CHU Hôtel Dieu - Nantes, Nantes

Hospital General Mexico, Mexico City

Hospital de Dona Estefânia - CHLC, Lisbon

Centro Materno-Infantil de Norte, Porto

FAM-CRU, Cape Town

PHRU, Soweto

Hospital San Joan de Deu, Barcelona

Hospital Clínico San Carlos, Madrid

Hospital General Gregorio Marañón, Madrid

Hospital La Paz, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario de Getafe, Madrid

Inselpital Bern, Bern

Kantonsspital St Gallen, Sankt Gallen

Kinderspital Zurich, Zurich

Prapokklao Hospital, Chanthaburi

Nakornping Hospital, Chiang Mai

Chiangrai Prachanukroh Hospital, Chiang Rai

Kalasin hospital, Kalasin

Khonkaen hospital, Khon Kaen

Phayao hospital, Phayao

Baylor, Kampala

JCRC, Mbarara

Kiev, Kiev

Kryvyi Rih, Kryvyi Rih

Birmingham Heartlands Hospital, Birmingham

Bristol Hospital, Bristol

Evelina Children Hospital, St Thomas's Hospital, London

King's College Hospital, London

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

MRC CTU at UCL

UNKNOWN

collaborator

PHPT

UNKNOWN

lead

PENTA Foundation

NETWORK

NCT02383108 - Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children | Biotech Hunter | Biotech Hunter